DETECT-IP: a Clinical Decision Support System and Intelligent Procedures to Counter Some Adverse Drug Events in Older Hospital Patients

Acute Renal Failure Clinical Trial

— DETECT-IP:  

Official title:

Reduction of Acute Renal Failure and/or Hyperkaliemia Adverse Drug Events in Older Inpatients by Incorporating Specific Rules Into a Computerized Support System and Dedicated Procedures: a Randomized Trial.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05923983
• Other study ID #: 2019_1030
• Secondary ID: 2021-A03211-40AA
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2023
• Est. completion date: July 2024

Study information

• Verified date: June 2023
• Source: University Hospital, Lille
• Contact: Jean-Baptiste Beuscart, MD
• Phone: 0320445962
• Email: jean-baptiste.beuscart[@]univ-lille.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Current evidence shows that computerized decision support systems (CDSS) have shown to be insufficiently effective to prevent adverse drug reactions (ADRs) at large scale (e.g. whole hospital). Several barriers for successful implementation of CDSS have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. The effectiveness of CDSS could be increased in two ways. Firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent ADR in older hospitalized patients). Secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. This procedure will reduce over-alerting and prevent task interruption. The hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a CDSS, combined with a strategy for managing and transmitting alerts, can reduce specific ADRs such as hyperkalemia and acute renal failure.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 4920
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized for 3 days or more in an MCO (medicine surgery obstetrics) department participating in the study
• Patient who gave oral consent to participate in the study
• Socially insured patient

Exclusion Criteria:

• Patient discharged or died before D3 of hospitalization
• Patient in palliative care or end of life on entry to the service
• Person under legal protection (curatorship)
• Lack of coverage by the social security system, Failure to obtain oral consent to participate in the study

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Renal Failure
• Drug-Related Side Effects and Adverse Reactions
• Patient Acceptance of Health Care
• Renal Insufficiency

Intervention

Other:
• Clinical decision support
In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
• Will not receive Clinical Decision Support
In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Lille	OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations, Regional Agency of Sante Nord Pas-de-Calais

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse drug events such as acute renal failure and/or hyperkalemia in older hospitalized patients.		through study completion, an average of 20 days
Secondary	Presence of an adverse event related to the intervention provided ("change of prescription", "discontinuation of drug")		through study completion, an average of 20 days
Secondary	Therapeutic adaptations implemented in case of acute renal failure (ARF) or hyperkalemia upon hospital admission	Therapeutic changes within 72 hours of a CDSS alert for acute renal failure or hyperkalemia. Therapeutic changes include discontinuation of drug therapy, introduction of a new drug, dose reduction or change of drug	through study completion, an average of 15 days
Secondary	Relevance of CDSS alerts	Relevance of CDSS alerts is defined in a standard way. Each CDSS alert is evaluated by a clinical pharmacist according to their own expertise and data available in the EHR. If the alert was deemed not relevant, the clinical pharmacist did not perform any pharmaceutical intervention. The CDSS software register the classification of the alert as "not relevant". This approach was used the last 4 years in our hospital and as been published in an article published in the International Journal of Medical Informatics: Cuvelier E, Robert L, Musy E, Rousselière C, Marcilly R, Gautier S, Odou P, Beuscart JB, Décaudin B. The clinical pharmacist's role in enhancing the relevance of a clinical decision support system. Int J Med Inform. 2021 Nov;155:104568. doi: 10.1016/j.ijmedinf.2021.104568. Epub 2021 Sep 2. PMID: 34537687	through study completion, an average of 20 days
Secondary	Number of pharmaceutical interventions accepted	When an alert is received by the pharmacist, it is analyzed and the pharmacist forwards a pharmaceutical intervention to the physician in charge of the patient to propose a modification of the treatment (dosage, dose, stop	through study completion, an average of 20 days
Secondary	Changes in ADEs (Adverse Drug Event) prevention/management work process induced by the introduction of alerts	Changes in the work system are identified through a comparison of its elements (tools, tasks, organization, interactions, work environment, professionals), before and after the introduction of alerts, using qualitative system engineering methods.	Through study completion, an average of 20 days
Secondary	Cost-effectiveness of the pharmaceutical intervention	Use medico-economic data such as time spent treating an alert, cost of treating an adverse drug reaction to estimate the cost-effectiveness of the intervention	through study completion, an average of 20 days